Or\u00e1lna aplik\u00e1cia na v\u00edrus COVID-19. Spolo\u010dnos\u0165 Pfizer, Merck za\u010d\u00edna nov\u00e9 sk\u00fa\u0161ky or\u00e1lnej lie\u010dby SARS-CoV-2, liek Molnupiravir. Pfizer a Merck & Co ozn\u00e1mili nov\u00e9 testy svojej experiment\u00e1lnej or\u00e1lnej antiv\u00edrusovej lie\u010dby COVID-19. Lie\u010divo je navrhnut\u00e9 tak, aby blokovalo aktivitu k\u013e\u00fa\u010dov\u00e9ho enz\u00fdmu zapojen\u00e9ho do replik\u00e1cie v\u00edrusu. Liekov\u00e1 lie\u010dba v\u00edrusu COVID-19.<\/p>\n
Spolo\u010dnosti Pfizer Inc a Merck & Co Inc v stredu ozn\u00e1mili nov\u00e9 sk\u00fa\u0161ky svojich experiment\u00e1lnych peror\u00e1lnych antiv\u00edrusov\u00fdch liekov na SARS-CoV-2, preto\u017ee sa rozbiehaj\u00fa preteky vo v\u00fdvoji \u013eahko pod\u00e1vate\u013enej lie\u010dby potenci\u00e1lne smrte\u013en\u00e9ho ochorenia. Spolo\u010dnos\u0165 Pfizer uviedla, \u017ee do najnov\u0161ej \u0161t\u00fadie v strednom a\u017e neskorom \u0161t\u00e1diu bude zaraden\u00fdch 1140 nehospitalizovan\u00fdch dospel\u00fdch s diagnostikovanou koronav\u00edrusovou infekciou, ktor\u00fdm nehroz\u00ed v\u00e1\u017ene ochorenie. <\/p>\n
Pacienti v sk\u00fa\u0161an\u00ed dostan\u00fa pilulku Pfizer, zn\u00e1mu ako PF-07321332, a n\u00edzku d\u00e1vku ritonaviru, star\u0161ieho lieku, ktor\u00fd sa \u0161iroko pou\u017e\u00edva v kombinovanej lie\u010dbe infekcie HIV.<\/p>\n
Lie\u010divo Pfizer je navrhnut\u00e9 tak, aby blokovalo aktivitu k\u013e\u00fa\u010dov\u00e9ho enz\u00fdmu, ktor\u00fd je potrebn\u00fd na mno\u017eenie koronav\u00edrusu.<\/p>\n
Spolo\u010dnos\u0165 Merck uviedla, \u017ee jej nov\u00e1 \u0161t\u00fadia bude sk\u00fama\u0165 experiment\u00e1lny liek molnupiravir na prevenciu COVID-19 medzi dospel\u00fdmi v tej istej dom\u00e1cnosti, ako je niekto s diagnostikovanou symptomatickou koronav\u00edrusovou infekciou. Spolo\u010dnos\u0165 Merck a partner Ridgeback Biotherapeutics u\u017e vykon\u00e1vaj\u00fa neskor\u00e9 \u0161t\u00e1dium sk\u00fa\u0161ania lie\u010dby u nehospitalizovan\u00fdch pacientov, aby zistili, \u010di to zni\u017euje riziko hospitaliz\u00e1cie alebo smrti.<\/p>\n
Molnupiravir je typ antivirotika navrhnut\u00e9ho tak, aby zaviedol do RNA v\u00edrusu chyby, ktor\u00e9 mu nakoniec zabr\u00e1nia v replik\u00e1cii.<\/p>\n
Spolo\u010dnos\u0165 Pfizer za\u010dala v j\u00fali in\u00fa \u0161t\u00fadiu PF-07321332 u dospel\u00fdch s infekciou COVID-19, u ktor\u00fdch je vysok\u00e9 riziko v\u00e1\u017eneho ochorenia v d\u00f4sledku z\u00e1kladn\u00fdch zdravotn\u00fdch stavov, ako je diabetes. Spolo\u010dnos\u0165 uviedla, \u017ee po\u010diato\u010dn\u00e9 v\u00fdsledky tejto \u0161t\u00fadie o\u010dak\u00e1va niekedy na jese\u0148 tohto roku. Rivals Pfizer a Merck spolu so \u0161vaj\u010diarskou farmaceutickou spolo\u010dnos\u0165ou Roche Holding AG urobili najv\u00e4\u010d\u0161\u00ed pokrok vo v\u00fdvoji prvej antiv\u00edrusovej pilulky na lie\u010dbu SARS-CoV-2 alebo na jej prevenciu.<\/p>\n
K dne\u0161n\u00e9mu d\u0148u je intraven\u00f3zny liek Veklury spolo\u010dnosti Gilead Sciences Inc, v\u0161eobecne zn\u00e1my ako remdesivir, jedinou schv\u00e1lenou antiv\u00edrusovou lie\u010dbou na SARS-CoV-2 v USA.<\/p>\n
Roche a partner Atea Pharmaceuticals v j\u00fani uviedli, \u017ee v\u010dasn\u00e9 \u00fadaje zo \u0161t\u00fadie ich experiment\u00e1lneho peror\u00e1lneho antiv\u00edrusov\u00e9ho lieku AT-527 uk\u00e1zali, \u017ee zni\u017euje v\u00edrusov\u00fa z\u00e1\u0165a\u017e u hospitalizovan\u00fdch pacientov. Spolo\u010dnos\u0165 Merck v j\u00fani uviedla, \u017ee americk\u00e1 vl\u00e1da s\u00fahlasila s zaplaten\u00edm pribli\u017ene 1,2 miliardy dol\u00e1rov za 1,7 mili\u00f3na k\u00far molnupiraviru, ak sa preuk\u00e1\u017ee, \u017ee funguj\u00fa a s\u00fa schv\u00e1len\u00e9 regula\u010dn\u00fdmi org\u00e1nmi. Spolo\u010dnos\u0165 uviedla, \u017ee o\u010dak\u00e1va, \u017ee pod\u00e1 \u017eiados\u0165 o autoriz\u00e1ciu molnupiraviru v USA na n\u00fadzov\u00e9 pou\u017eitie najsk\u00f4r v druhej polovici roku 2021.<\/p>\n
Spolo\u010dnos\u0165 Pfizer v j\u00fali uviedla, \u017ee ak bude test PF-07321332 \u00faspe\u0161n\u00fd, vo \u0161tvrtom \u0161tvr\u0165roku pod\u00e1 \u017eiados\u0165 o potenci\u00e1lne povolenie na n\u00fadzov\u00e9 pou\u017eitie.<\/p><\/blockquote>\n
Peror\u00e1lna lie\u010dba COVID-19. Americk\u00fd liek m\u00f4\u017ee zastavi\u0165 pokrok v izraelskom v\u00fdskume COVID-19. Peror\u00e1lne dostupn\u00fd kandid\u00e1t na antiv\u00edrusov\u00e9 lieky Molnupiravir m\u00e1 potenci\u00e1l zabr\u00e1ni\u0165 hospitaliz\u00e1cii, ak sa pod\u00e1va miernym alebo stredne \u0165a\u017ek\u00fdm pacientom.<\/p>\n
si 50% potrebn\u00fdch pacientov bolo prijat\u00fdch na dokon\u010denie \u0161t\u00fadie f\u00e1zy III s americky vyvinut\u00fdm liekom, ktor\u00fd \u201em\u00f4\u017ee zmeni\u0165 hru\u201c v boji proti COVID-19, hovor\u00ed profesor Yosef Caraco z Hadassah University Medical Center.<\/p>\n
Caraco pre denn\u00edk The Jerusalem Post uviedol, \u017ee jeho t\u00edm ned\u00e1vno dokon\u010dil \u010das\u0165 \u00faspe\u0161nej sk\u00fa\u0161ky f\u00e1zy II peror\u00e1lne dostupn\u00e9ho antiv\u00edrusov\u00e9ho lieku Molnupiravir vyvinut\u00e9ho spolo\u010dnos\u0165ou Merck Pharmaceuticals (medzin\u00e1rodne pr\u00e1vne zn\u00e1mej ako MSD), lieku ur\u010den\u00e9ho na spomalenie progresie koronav\u00edrusu z mierneho k \u0165a\u017ek\u00fdm chorob\u00e1m.<\/p>\n
Profesor predstavil \u00fadaje zo \u0161t\u00fadie na eur\u00f3pskom kongrese klinickej mikrobiol\u00f3gie a infek\u010dn\u00fdch chor\u00f4b v j\u00fali. \u0160t\u00fadia sa uskuto\u010dnila v 80 zdravotn\u00edckych stredisk\u00e1ch po celom svete, na ktor\u00fdch sa z\u00fa\u010dastnilo asi 300 pacientov s koronav\u00edrusom v miernom alebo stredne \u0165a\u017ekom stave. Niektor\u00ed dost\u00e1vali Molnupiravir a in\u00ed placebo.<\/p>\n
“V\u0161eobecn\u00fd z\u00e1ver z tejto f\u00e1zy je, \u017ee v prvom rade je liek bezpe\u010dn\u00fd,” povedal Caraco. “Nepozorovali sme ni\u010d neobvykl\u00e9. Tie\u017e sme videli, \u017ee u t\u00fdch, ktor\u00ed boli lie\u010den\u00ed t\u00fdmto liekom, bola men\u0161ia pravdepodobnos\u0165, \u017ee bud\u00fa potrebova\u0165 hospitaliz\u00e1ciu v porovnan\u00ed s t\u00fdmi, ktor\u00ed dost\u00e1vali placebo. \u201c<\/p>\n
Ako tak\u00fd povedal: \u201eM\u00f4\u017eeme opatrne poveda\u0165, \u017ee liek m\u00e1 potenci\u00e1l zabr\u00e1ni\u0165 hospitaliz\u00e1cii, ak je pod\u00e1van\u00fd mierne alebo stredne chor\u00fdm pacientom, najm\u00e4 ak je podan\u00fd na za\u010diatku priebehu choroby.\u201c<\/p>\n
Sk\u00fa\u0161ka f\u00e1zy II trvala od konca jesene 2020 do apr\u00edla 2021. \u0160t\u00fadia f\u00e1zy III, ktor\u00e1 sa za\u010dala v j\u00fani, by mala trva\u0165 \u010fal\u0161\u00edch nieko\u013eko mesiacov. Pod\u013ea Caraca u\u017e bolo prijat\u00fdch p\u00e4\u0165desiat percent pacientov.<\/p>\n
Dodal, \u017ee liek je \u00fa\u010dinn\u00fd proti koronav\u00edrusu a m\u00f4\u017ee zastavi\u0165 priebeh infekcie od miernej alebo stredne z\u00e1va\u017enej po z\u00e1va\u017en\u00fa.
\n“Doteraz sme boli ve\u013emi zanepr\u00e1zdnen\u00ed v\u00fdskumom liekov na lie\u010dbu naj\u0165a\u017e\u0161\u00edch pacientov v nemocnici,” povedal Caraco. <\/p>\n“Je to celkom zrejm\u00e9, preto\u017ee hovor\u00edme o \u013eu\u010foch ohrozen\u00fdch smr\u0165ou.”<\/p>\n","protected":false},"excerpt":{"rendered":"
Or\u00e1lna aplik\u00e1cia na v\u00edrus COVID-19. Spolo\u010dnos\u0165 Pfizer, Merck za\u010d\u00edna nov\u00e9 sk\u00fa\u0161ky or\u00e1lnej lie\u010dby SARS-CoV-2, liek Molnupiravir. Pfizer a Merck & Co ozn\u00e1mili nov\u00e9 testy svojej experiment\u00e1lnej or\u00e1lnej antiv\u00edrusovej lie\u010dby COVID-19. Lie\u010divo je navrhnut\u00e9 tak, aby blokovalo aktivitu k\u013e\u00fa\u010dov\u00e9ho enz\u00fdmu zapojen\u00e9ho do replik\u00e1cie v\u00edrusu. Liekov\u00e1 lie\u010dba v\u00edrusu COVID-19. Or\u00e1lna lie\u010dba COVID-19, Pfizer a Merck, liek Molnupiravir […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-17083","post","type-post","status-publish","format-standard","hentry","category-exo-news"],"_links":{"self":[{"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/posts\/17083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/comments?post=17083"}],"version-history":[{"count":0,"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/posts\/17083\/revisions"}],"wp:attachment":[{"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/media?parent=17083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/categories?post=17083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/extraslovensko.sk\/spravy\/wp-json\/wp\/v2\/tags?post=17083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}